Lam Research Corporation
$383.16B- Market cap
- $385.02B
- Debt
- +$3.72B
- Cash
- −$5.58B
Capital structure 99% equity / 1% debt · EV / Revenue 16.49x · EV / EBITDA 43.55x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LRCX stock price at premium vs EVH $307.69 current versus $4.84 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EVH's multiple
Implied fair value · at LRCX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LRCX FY 2026 (ended Jun 28, 2026) · EVH FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 16.49x · EV / EBITDA 43.55x
Capital structure 34% equity / 66% debt · EV / Revenue 0.70x
LRCX carries the larger enterprise value at $383.16B against $1.31B; EVH trades on the lower EV / Revenue multiple (0.70x vs 16.49x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LAM RESEARCH CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Evolent Health, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.30x
2.34x
Net debt / EBITDA
Leverage against operating earnings
-0.21x
-2.11x
Cash and equivalents
Liquid reserves on the balance sheet
$5.58B
$151.86M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Applied Materials, Inc.
LRCX vs AMAT
KLA CORP
LRCX vs KLAC
ASML HOLDING NV
LRCX vs ASML
TERADYNE, INC
LRCX vs TER
ENTEGRIS INC
LRCX vs ENTG
Cigna Group
LRCX vs CI
MOLINA HEALTHCARE, INC.
LRCX vs MOH
Teladoc Health, Inc.
LRCX vs TDOC
CLOVER HEALTH INVESTMENTS, CORP. /DE
LRCX vs CLOV
UNITEDHEALTH GROUP INC
LRCX vs UNH
$3.72B
$970.54M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.